USFDA inspection at Visakhapatnam facilities concluded with zero observations

Regulatory & Legal View source PDF Explain this filing

GLAND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.5%Reaction day

₹2884.00

prior close

₹2915.00

announcement price

After-mkt

timing

Nifty Smallcap 250market-0.6%+0.1% vs market

Pharmaceuticals peers, median of 171sector-0.1%-0.3% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Smallcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

-2.8

15m

-2.0

30m

-2.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.5-0.6+0.1-0.1-0.3

Next day

+0.8+0.4+0.3+0.2+0.5

+1.9+0.6+1.3+0.1+1.8

+3.1+0.7+2.4+0.6+2.5

+2.6+0.9+1.7+0.8+1.9

+4.7+0.4+4.3+0.0+4.7

+1.5-0.1+1.7+0.5+1.0

15d

+0.1-1.1+1.2+0.8-0.8

+0.6-3.9+4.4-2.1+2.7

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The USFDA completed a routine GMP inspection at Gland Pharma's VSEZ Sterile Oncology Formulations Facility and API Facility in Visakhapatnam from August 24 to September 1, 2026. The inspection closed with zero Form 483 observations, meaning no compliance issues were flagged by the regulator.

Likely market impact

Positive for shareholders - clean USFDA inspection with no observations signals strong compliance and supports uninterrupted US market supplies.